Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

OFATUMUMAB vs OLMESARTAN MEDOXOMIL: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

OFATUMUMAB vs OLMESARTAN MEDOXOMIL: Safety Overview

Metric OFATUMUMAB OLMESARTAN MEDOXOMIL
Total FAERS Reports 29,913 11,972
Deaths Reported 695 283
Death Rate 2.3% 2.4%
Hospitalizations 3,616 6,564
Average Patient Age 47.5 yrs 66.9 yrs
% Female Patients 74.9% 56.6%
FDA Approval Date N/A Apr 13, 2020
Manufacturer Novartis Pharmaceuticals Corporation direct rx
Route INTRAVENOUS ORAL
Marketing Status Prescription Prescription